PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PEPG PepGen Inc.

Trading 12-18 09:31:12 EST

5.24

-0.03

-0.57%

High5.25	Low5.22	Vol1.64K
Open5.25	D1 Closing5.27	Amplitude0.51%
Mkt Cap360.24M	Tradable Cap239.87M	Total Shares68.75M
T/O8.59K	T/O Rate0.00%	Tradable Shares45.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PEPG","market":"US","secType":"STK","nameCN":"PepGen Inc.","latestPrice":5.24,"timestamp":1766068220484,"preClose":5.27,"halted":0,"volume":1641,"delay":0,"floatShares":45776899,"shares":68748224,"eps":-2.82617,"marketStatus":"Trading","change":-0.03,"latestTime":"12-18 09:31:12 EST","open":5.25,"high":5.25,"low":5.2232,"amount":8588.3433435,"amplitude":0.005085,"askPrice":5.27,"askSize":100,"bidPrice":5.23,"bidSize":8,"shortable":3,"etf":0,"ttmEps":-2.82617,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766091600000},"marketStatusCode":2,"adr":0,"listingDate":1651809600000,"exchange":"NASDAQ","adjPreClose":5.27,"preHourTrading":{"tag":"盘前","latestPrice":5.2652,"preClose":5.27,"latestTime":"08:45 EST","volume":1,"amount":5.2652,"timestamp":1766065511153},"postHourTrading":{"tag":"盘后","latestPrice":5.27,"preClose":5.27,"latestTime":"19:27 EST","volume":1707,"amount":8995.76,"timestamp":1766017669454},"volumeRatio":0.873539,"impliedVol":1.745,"impliedVolPercentile":0.832},"requestUrl":"/m/hq/s/PEPG","defaultTab":"news","newsList":[{"id":"2590355515","title":"PepGen Inc. Files Initial Statement of Beneficial Ownership for Chief Business & Legal Officer Joseph Vittiglio","url":"https://stock-news.laohu8.com/highlight/detail?id=2590355515","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590355515?lang=en_us&edition=fundamental","pubTime":"2025-12-11 06:05","pubTimestamp":1765404333,"startTime":"0","endTime":"0","summary":"PepGen Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Joseph Vittiglio, Chief Business & Legal Officer of PepGen Inc., as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLC6Wh6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"PepGen Inc. Files Initial Statement of Beneficial Ownership for Chief Business & Legal Officer Joseph Vittiglio","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"gpt_icon":0},{"id":"2590343137","title":"PepGen Grants Stock Options to New Chief Business and Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343137","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343137?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:00","pubTimestamp":1765281647,"startTime":"0","endTime":"0","summary":"PepGen Inc. has awarded a non-qualified stock option grant to its newly appointed Chief Business and Legal Officer, Joseph Vittiglio. Under the 2024 Inducement Plan, Mr. Vittiglio received an option to purchase 160,000 shares of PepGen's common stock at an exercise price of $5.59 per share, the closing price on December 8, 2025. The stock option has a ten-year term and is set to vest over four years, with 25% vesting on the one-year anniversary of his employment start date and the remainder vesting in equal monthly installments over the next three years, contingent on continued service with the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. published the original content used to generate this news brief via Busines","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL1NY47r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2590343174","title":"PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) to Newly Appointed Chief Business and Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343174?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:00","pubTimestamp":1765281603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA5DSPQQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2589358384","title":"BRIEF-PepGen Appoints Joseph Vittiglio, Esq., As Chief Business And Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589358384","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589358384?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:36","pubTimestamp":1765197410,"startTime":"0","endTime":"0","summary":"BRIEF-PepGen Appoints Joseph Vittiglio, Esq., As Chief Business And Legal OfficerDec 8 (Reuters) - PepGen Inc PEPG.O:PEPGEN APPOINTS JOSEPH VITTIGLIO, ESQ., AS CHIEF BUSINESS AND LEGAL OFFICERSource text: ID:nBw80f3JhaFurther company coverage: PEPG.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA3VHDFB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"gpt_icon":0},{"id":"2589333725","title":"PepGen Names Joseph Vittiglio Chief Business and Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589333725","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589333725?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:00","pubTimestamp":1765195225,"startTime":"0","endTime":"0","summary":"PepGen Inc. has appointed Joseph Vittiglio, Esq., as Chief Business and Legal Officer. Vittiglio brings over 20 years of executive experience in public biotechnology companies and previously held senior roles at bluebird bio, Finch Therapeutics, and AMAG Pharmaceuticals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. published the original content used to generate this news brief via Business Wire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL2j7zJb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FNCH","BK4139","PEPG"],"gpt_icon":0},{"id":"2589337214","title":"PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589337214","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589337214?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:00","pubTimestamp":1765195203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUA3VHDFB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2583965622","title":"PepGen Inc. (PEPG) Gets a Sell from Bank of America Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2583965622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583965622?lang=en_us&edition=fundamental","pubTime":"2025-11-16 01:35","pubTimestamp":1763228122,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on PepGen Inc. yesterday and set a price target of $3.00. The company’s sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/pepgen-inc-pepg-gets-a-sell-from-bank-of-america-securities-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/pepgen-inc-pepg-gets-a-sell-from-bank-of-america-securities-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","LU0417517546.SGD","LU0477156953.USD","LU0203345920.USD","LU0170899867.USD","IE00BLSP4239.USD","LU0320765489.SGD","LU0203347892.USD","LU1496350171.SGD","LU0477156797.USD","LU1280957306.USD","BK4559","IE00B19Z3B42.SGD","BAC","LU0098860793.USD","IE00B7SZLL34.SGD","LU0980610538.SGD","LU0306806265.USD","LU0052756011.USD","BK4581","LU0640476718.USD","LU0053666078.USD","LU1035773651.USD","LU1496350502.SGD","LU1883839398.USD","IE00B1BXHZ80.USD","LU0130518102.USD","LU2133065610.SGD","LU0208291251.USD","IE00BBT3K403.USD","LU2265009873.SGD","PEPG","BK4534","BK4553","LU0310800965.SGD","LU0130517989.USD","LU1201861165.SGD","IE0002270589.USD","LU1201861249.SGD","LU0787776722.HKD","LU0971096721.USD","IE00BLSP4452.SGD","IE00BKVL7J92.USD","LU1880398554.USD","LU0321505868.SGD","BK4585","LU0683600562.USD","LU0070302665.USD","LU1506573853.SGD","LU0130102774.USD"],"gpt_icon":0},{"id":"2583259306","title":"Wedbush Raises Price Target on PepGen to $9 From $8, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2583259306","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583259306?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:48","pubTimestamp":1763041724,"startTime":"0","endTime":"0","summary":"PepGen (PEPG) has an average rating of overweight and mean price target of $9.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PEPG","BK4139"],"gpt_icon":0},{"id":"2583939665","title":"PepGen price target raised to $20 from $18 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2583939665","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583939665?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:36","pubTimestamp":1763040967,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andrew Fein raised the firm’s price target on PepGen (PEPG) to $20 from $18 and keeps a Buy rating on the shares. A new U.S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pepgen-price-target-raised-to-20-from-18-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pepgen-price-target-raised-to-20-from-18-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2583534313","title":"PepGen Inc. Strengthens Financial Position Amid Ongoing Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2583534313","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583534313?lang=en_us&edition=fundamental","pubTime":"2025-11-13 12:07","pubTimestamp":1763006848,"startTime":"0","endTime":"0","summary":"PepGen Inc. ( ($PEPG) ) has released its Q3 earnings. Here is a breakdown of the information PepGen Inc. presented to its investors. PepGen Inc. is...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pepgen-inc-strengthens-financial-position-amid-ongoing-losses?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pepgen-inc-strengthens-financial-position-amid-ongoing-losses?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PEPG","BK4139"],"gpt_icon":0},{"id":"2582740413","title":"PepGen Receives US Patent for Investigational Candidate for Severe Neuromuscular Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2582740413","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582740413?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:55","pubTimestamp":1762955742,"startTime":"0","endTime":"0","summary":"PepGen  said Wednesday it has received a new patent from the US Patent and Trademark Office for PGN-EDODM1, its investigational candidate being developed to treat myotonic dystrophy type 1 -- a severe nueromuscular disease.The therapy candidate utilizes the company's Enhanced Delivery Oligonucleotide platform, the company said.The new patent will expire in H2 2042, with the possibility of an extension after US Food and Drug Administration approval of PGN-EDODM1, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PEPG","BK4139"],"gpt_icon":0},{"id":"2582482376","title":"PepGen announces issuance of patent for PGN-EDODM1","url":"https://stock-news.laohu8.com/highlight/detail?id=2582482376","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582482376?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:36","pubTimestamp":1762950988,"startTime":"0","endTime":"0","summary":"PepGen (PEPG) announced that the United States Patent and Trademark Office has issued the company a new composition of matter patent covering PGN-E...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pepgen-announces-issuance-of-patent-for-pgn-edodm1-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pepgen-announces-issuance-of-patent-for-pgn-edodm1-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2582375574","title":"PepGen Inc - Patent Provides Exclusivity for Pgn-Edodm1 in U.S. Until 2042","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375574?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:13","pubTimestamp":1762949632,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO0PP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PEPG","BK4139"],"gpt_icon":0},{"id":"2582375546","title":"PepGen Q3 EPS $(0.52) Beats $(0.59) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375546","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375546?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:12","pubTimestamp":1762949523,"startTime":"0","endTime":"0","summary":"PepGen Q3 EPS $(0.52) Beats $(0.59) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48799206/pepgen-q3-eps-0-52-beats-0-59-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"gpt_icon":0},{"id":"2582756643","title":"Biotech firm PepGen's Q3 net loss narrows to $18 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2582756643","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582756643?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:11","pubTimestamp":1762949461,"startTime":"0","endTime":"0","summary":"Biotech firm PepGen's Q3 net loss narrows to $18 mlnOverviewPepGen Q3 net loss narrows to $18 mln from $21.4 mln in 2024Company raised $115 mln, extending cash runway into 2H 2027FREEDOM-DM1 study sho","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0D4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"gpt_icon":0},{"id":"2582833375","title":"PepGen Inc. Granted U.S. Patent for Proprietary PGN-EDODM1 Molecule, Extending Exclusivity Into 2042","url":"https://stock-news.laohu8.com/highlight/detail?id=2582833375","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582833375?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:05","pubTimestamp":1762949126,"startTime":"0","endTime":"0","summary":"PepGen Inc. announced that the United States Patent and Trademark Office has issued a new composition of matter patent for PGN-EDODM1, a molecule developed using the company's proprietary Enhanced Delivery Oligonucleotide  platform. The patent, which covers the unique peptide and linker chemistry of PGN-EDODM1, is expected to provide exclusivity in the U.S. into the second half of 2042, with the potential for patent term extension following FDA approval. The patent, numbered 12,465,646, adds to PepGen's growing global patent portfolio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. published the original content used to generate this news brief via Business Wire  on November 12, 2025, and is solely responsible for the infor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL970hX9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2582373169","title":"BRIEF-PepGen Q3 EPS USD -0.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373169","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373169?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948846,"startTime":"0","endTime":"0","summary":"BRIEF-PepGen Q3 EPS USD -0.52\n\n\nNov 12 (Reuters) - PepGen Q3 operating income USD -18.654 million.\n\nQ3 net income USD -18.026 million\nQ3 operating expenses USD 18.654 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXBA5EFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2582373168","title":"PepGen reports third quarter net loss of $18.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373168","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373168?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948838,"startTime":"0","endTime":"0","summary":"PepGen Inc. reported a net loss of $18.0 million, or $ per basic and diluted share, for the three months ended September 30, 2025, compared to a net loss of $21.4 million, or $ per share, in the same period of 2024. Research and development expenses were $13.4 million, down from $17.7 million, while general and administrative expenses were $5.2 million, compared to $5.4 million in the previous year. As of September 30, 2025, PepGen held $163.7 million in cash, cash equivalents, and marketable securities, with a cash runway projected into the second half of 2027. During the quarter, the company highlighted positive clinical data from its FREEDOM-DM1 program and completed enrollment in the FREEDOM2-DM1 study, with a readout expected in the first quarter of 2026. PepGen also completed a $115 million financing round.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL1S1DDb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2582373637","title":"PepGen Q3 Operating Expenses USD 18.654 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373637","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373637?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXBA5EFF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2582237327","title":"Press Release: PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2582237327","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582237327?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948800,"startTime":"0","endTime":"0","summary":"-- FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients --. -- FREEDOM2-DM1 5 mg/kg cohort on track to readout in Q1 2026, with all patients enrolled and having received at least one dose --. -- Recent $115 million financing extends cash runway into the second half of 2027 --. PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2025.first quarter of 2026 and expects to initiate dosing i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0728928796.USD","LU1165135440.EUR","IE00BN0W2T93.GBP","LU2308191902.HKD","LU2413666004.HKD","LU1923621640.USD","LU1620156130.USD","LU2413665964.HKD","LU1169589451.USD","LU1620156213.USD","LU0757428866.USD","LU1543694498.USD","LU1815336091.USD","LU1721427968.SGD","LU0054578231.USD","LU2125910179.SGD","BK4139","LU2229751404.USD","LU0012050646.USD","LU1169590202.USD","LU2089279066.USD","LU2125910336.SGD","PEPG","IE00BN0W2W23.USD","LU0106261612.USD","IE00BN0W2V16.EUR","BK4086","WMS","LU1596574779.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pepgen.com","stockEarnings":[{"period":"1week","weight":-0.0991},{"period":"1month","weight":-0.015},{"period":"3month","weight":1.5707},{"period":"6month","weight":2.6345},{"period":"1year","weight":0.2256},{"period":"ytd","weight":0.3905}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.005448},{"month":2,"riseRate":0.666667,"avgChangeRate":0.703128},{"month":3,"riseRate":0,"avgChangeRate":-0.295265},{"month":4,"riseRate":0.666667,"avgChangeRate":0.062221},{"month":5,"riseRate":0.333333,"avgChangeRate":0.08415},{"month":6,"riseRate":0,"avgChangeRate":-0.194547},{"month":7,"riseRate":0.5,"avgChangeRate":-0.062921},{"month":8,"riseRate":0.25,"avgChangeRate":-0.102699},{"month":9,"riseRate":0.25,"avgChangeRate":0.658187},{"month":10,"riseRate":0.75,"avgChangeRate":0.035806},{"month":11,"riseRate":0.5,"avgChangeRate":0.080021},{"month":12,"riseRate":0.25,"avgChangeRate":-0.037428}],"exchange":"NASDAQ","name":"PepGen Inc.","nameEN":"PepGen Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest PepGen Inc.(PEPG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"PepGen Inc.,PEPG,PepGen Inc.股票,PepGen Inc.股票老虎,PepGen Inc.股票老虎国际,PepGen Inc.行情,PepGen Inc.股票行情,PepGen Inc.股价,PepGen Inc.股市,PepGen Inc.股票价格,PepGen Inc.股票交易,PepGen Inc.股票购买,PepGen Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest PepGen Inc.(PEPG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction